Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Sep 20;10(9):1130. doi: 10.3390/antibiotics10091130

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

For 12 patients started beyond the therapeutic target (a) Distinction of voriconazole trough concentration in different CYP2C19 phenotype groups (n = 50, p = 0.021). The Kruskal–Wallis test was used to compare C_mins. (b) Distinction of voriconazole trough concentration in different groups of C₀, C₁, C_ss (n = 50), and daily dose (n = 27). Data are expressed as the median ± interquartile range. (c) The mean concentration of such 12 patients changed by days. (d) Every dosage adjustment (n = 247) and the mode dose (n = 45) by days (It showed the highest one if there were more than one mode). *1, *2, *3, *17 reprented the single nucleotide sequence of genotype of CYP2C19.